Finding effective and safe way to reduce immunotoxic action of anticancer drugs without weakening their specific activity is the actual problem of modern medicine. In this regard, special attention was attracted to a national inducer of endogenous interferon amixin that is high means in the prevention and treatment of viral diseases and secondary immune deficiencies. However, the molecular mechanisms of action of immunotropic amixin and ability to use it for correcting violations of doxorubicin-induced immune disorders remain unclear. The aim was to study the role of cytokine-dependent processes in formation mechanisms of doxorubicin-induced immunosuppression and the establishment of opportunities for their pharmacological correction inducer of endogenous interferon amixin. It was found that 4-course treatment of mice with doxorubicin (1 time per week at a dose of 5.0 mg/kg) leads to inhibition of the activity of peritoneal macrophages and intensity of blasttransformation of peripheral blood lymphocytes as a result of violations of their sensitivity to the comitogenic effects of IL-1β in vitro. Prophylactic use of the inducer of endogenous interferon amixin reduces doxorubicin-induced disorders of cytokine producing activity of peritoneal macrophages, restores functional reserve lymphocyte activating factor production with additional stimulation of macrophages staphylococci in vitro and increases the sensitivity of peripheral blood lymphocytes to the modulating effects of IL-1β in reaction of blasttransformation of leukocytes.
